- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.05. | Elicera Therapeutics AB: Elicera Therapeutics enters a Material Transfer Agreement with University Hospital Tübingen for testing of the company's oncolytic virus candidates, ELC-100 and ELC-201 | 64 | GlobeNewswire (Europe) | Gothenburg, May 28, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology... ► Artikel lesen | |
| 22.05. | Elicera Therapeutics AB: Elicera reports: Active lymphoma eliminated in two out of three patients in the first cohort of the CARMA study with iTANK-armed CAR T-cell therapy | 102 | GlobeNewswire (Europe) | Gothenburg, May 22, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 15.05. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 31 March 2025 | 110 | GlobeNewswire (Europe) | First quarter (January-March 2025)
Operating loss amounted to SEK -8,069,404 (-5,433,422).
Loss for the period amounted to SEK -8,013,462 (-5,369,677).
Cash flow from operating activities totalled... ► Artikel lesen | |
| 14.04. | ELICERA THERAPEUTICS: Green light to continue Elicera's CARMA-trial in B-cell lymphoma | 2 | Cision News | ||
| 10.04. | Elicera Therapeutics AB: Elicera Therapeutics continues the Phase I/IIa CARMA study with its CAR T-cell therapy as planned following the safety committee's assessment of cohort 1 | 223 | GlobeNewswire (Europe) | Gothenburg, April 10, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 20.03. | Elicera Therapeutics resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO2 | 3 | Cision News | ||
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.03. | Warrants of series TO2 in Elicera Therapeutics AB were subscribed to approximately 96.3 percent and the company resolves on a directed issue to underwriters | 1 | Cision News | ||
| 07.03. | The last day of trading with the warrants of series TO2 in Elicera Therapeutics is today, March 7, 2025 | 2 | Cision News | ||
| 03.03. | ELICERA THERAPEUTICS: Elicera's CEO: "TO2 is a highly attractive opportunity to increase ownership in Elicera" | 2 | Cision News | ||
| 28.02. | Correction: Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics | 2 | Cision News | ||
| 28.02. | Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics | 1 | Cision News | ||
| 26.02. | Elicera Therapeutics - Positioned to deliver in cell and gene therapies | 334 | Edison Investment Research | Elicera Therapeutics is a cell and gene therapy company utilising its iTANK platform to develop immunotherapies for solid and bloodborne tumours. Its pipeline comprises two CAR-T therapies and two oncolytic... ► Artikel lesen | |
| 25.02. | Elicera Therapeutics has secured 100 percent of the warrants of series TO2 corresponding to approximately SEK 22.0 million | 1 | Cision News | ||
| 25.02. | The exercise price for the warrants of series TO2 in Elicera Therapeutics has been determined to SEK 1.85 | 2 | Cision News | ||
| 12.02. | Elicera Therapeutics receives partial payment of 0,5 MEur from EIC | 3 | Cision News | ||
| 12.02. | Elicera Therapeutics Receives Notification of Partial Payment of EUR 500,000 from the European Innovation Council Accelerator Programme | 2 | Cision News | ||
| 10.02. | Elicera Therapeutics Presents Initial Clinical Data from the CARMA Study at ISCT 2025 in New Orleans | 8 | Cision News | ||
| 05.02. | ELICERA THERAPEUTICS: Elicera's CEO: "2025 is a crucial year for us" | 1 | Cision News | ||
| 03.02. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Year-end Report 1 January - 31 December 2024 | 128 | GlobeNewswire (Europe) | Fourth quarter (October-December 2024)
Operating profit/loss amounted to SEK -2,911,958 (-5,212,694).
Loss for the period amounted to SEK -2,603,242 (-4,749,222).
Cash flow from operating activities... ► Artikel lesen | |
| 28.01. | ELICERA THERAPEUTICS: Elicera's CEO: "All signs of the disease disappeared in the first patient" | 1 | Cision News |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 434,60 | +0,44 % | Regeneron-Aktie crasht nach COPD-Daten - Verona Pharma schießt auf Allzeithoch | Bittere Pille für Regeneron Pharmaceuticals. Das Unternehmen und der Entwicklungspartner Sanofi haben in der vergangenen Handelswoche mit frischen Spätphasen-Studiendaten zum COPD-Hoffnungsträger Itepekimab... ► Artikel lesen | |
| BRAIN BIOTECH | 2,100 | +0,48 % | BRAIN Biotech: Wann kommt die Trendwende bei den Biokatalysatoren? | Die BRAIN Biotech AG (DE0005203947) kämpft mit einem schwierigen Marktumfeld. Im ersten Halbjahr 2024/25 ging der Umsatz um 7,2 Prozent auf 25,2 Millionen Euro zurück. Das Unternehmen spürt die Auswirkungen... ► Artikel lesen | |
| SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| CARDIOL THERAPEUTICS | 1,218 | -1,30 % | H.C. Wainwright initiates Cardiol Therapeutics stock with buy rating | ||
| BURCON NUTRASCIENCE | 0,073 | +5,80 % | Burcon NutraScience Corporation: Burcon to Participate in 2025 Canadian Climate Investor Conference | Vancouver, British Columbia--(Newsfile Corp. - May 28, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
| CSL | 136,82 | -1,03 % | CSL LIMITED: Notification of cessation of securities - CSL | ||
| MANNKIND | 3,790 | -1,28 % | MannKind bei Jefferies Global Healthcare: Strategisches Wachstum und Innovation | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,434 | +0,99 % | Oxford Nanopore Tech - Changes in Composition of Remuneration Committee | ||
| OCULAR THERAPEUTIX | 7,840 | -1,01 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, today announced that... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,250 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Reports Q1 Financial Results and Provides Business Update | TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced$4.0 million Tecelra net sales in Q1 2025Instituting 2025 Tecelra full year sales guidance of $35-$45... ► Artikel lesen | |
| CODEXIS | 2,000 | -3,66 % | Codexis, Inc.: Codexis Announces New Employment Inducement Grants | REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
| TELO GENOMICS | 0,050 | -11,50 % | Telo Genomics Corp.: Telo Genomics Receives New Client Tier under Intellectual Property Ontario (IPON) | Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human... ► Artikel lesen | |
| BIORA THERAPEUTICS | 1,260 | -100,00 % | NSE - BIORA THERAPEUTICS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| CORMEDIX | 11,600 | -5,69 % | CorMedix bei Jefferies Healthcare: Strategische Expansion und finanzielles Wachstum |
ELICERA THERAPEUTICS AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,023 (-4,14 %) liegt der Kurs bei 0,533 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.